Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Other Accumulated Expenses data on file, last reported at $109350.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 14.37% year-over-year to $109350.0 in Q1 2026; TTM through Mar 2026 was $109350.0, a 14.37% decrease from a year earlier, with the FY2025 full-year figure at $212927.0, up 162.87% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $109350.0, down from $212927.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for IKT reached as high as $2.7 million in Q1 2023 and fell as low as $100.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $212400.2 across 5 years, with a median of $32671.0 in 2022.
• On a YoY basis, Other Accumulated Expenses climbed as much as 14920.58% in 2023 and fell as far as 99.69% in 2023.
• Year by year, Other Accumulated Expenses stood at $9920.0 in 2022, then jumped by 936.46% to $102817.0 in 2023, then decreased by 21.22% to $81000.0 in 2024, then jumped by 162.87% to $212927.0 in 2025, then plunged by 48.64% to $109350.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $109350.0 in Q1 2026, $212927.0 in Q4 2025, and $116166.0 in Q3 2025.